Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maurizio D'Incalci

Showing results (1-10 of 233) with videos related to

Pageof 24
Sort By:
European Journal of Cancer (Oxford, England : 1990)|July 2, 2002
Editorial comment on "In vitro toxicity of ET-743 and Aplidine, two marine-derived antineoplastics, on human bone marrow haematopoietic progenitors: comparison with the clinical results" by Albella and colleaguesMaurizio D'Incalci
Future Oncology (London, England)|November 8, 2013
Trabectedin mechanism of action: what's new?Maurizio D'Incalci
European Journal of Cancer (Oxford, England : 1990)|December 23, 2008
Adjuvant 5-FU based chemotherapy for colon cancer: match or miss the mismatch?Maurizio D'Incalci
Tumori|August 8, 2007
Nitrosoureas: molecular pharmacology/ translational researchMaurizio D'Incalci
European Journal of Cancer (Oxford, England : 1990)|September 10, 2002
Professor Maurizio D'Incalci interviewed by Emma CannellMaurizio D'Incalci
Onkologie|June 14, 2006
Correlation of ErbB2 gene status, mRNA and protein expressionMaurizio D'Incalci
European Journal of Cancer (Oxford, England : 1990)|May 3, 2005
Are we close to the clinical development of novel drugs targeting telomeres and telomerase?Maurizio D'Incalci, Gabriella Zupi
Expert Opinion on Investigational Drugs|October 31, 2003
Preclinical and clinical results with the natural marine product ET-743Maurizio D'Incalci, José Jimeno
Tumori|May 28, 2011
Problems in dealing with very rare adverse effects of new anticancer drugs: the example of trabectedinFederica Grosso, Maurizio D'Incalci
European Journal of Cancer (Oxford, England : 1990)|September 19, 2009
Contemporary pre-clinical development of anticancer agents--what are the optimal preclinical models?Giovanna Damia, Maurizio D'Incalci
Pageof 24

Showing results (1-10 of 233) with videos related to

Sort By:
Pageof 24
European Journal of Cancer (Oxford, England : 1990)|July 2, 2002
Editorial comment on "In vitro toxicity of ET-743 and Aplidine, two marine-derived antineoplastics, on human bone marrow haematopoietic progenitors: comparison with the clinical results" by Albella and colleaguesMaurizio D'Incalci
Future Oncology (London, England)|November 8, 2013
Trabectedin mechanism of action: what's new?Maurizio D'Incalci
European Journal of Cancer (Oxford, England : 1990)|December 23, 2008
Adjuvant 5-FU based chemotherapy for colon cancer: match or miss the mismatch?Maurizio D'Incalci
Tumori|August 8, 2007
Nitrosoureas: molecular pharmacology/ translational researchMaurizio D'Incalci
European Journal of Cancer (Oxford, England : 1990)|September 10, 2002
Professor Maurizio D'Incalci interviewed by Emma CannellMaurizio D'Incalci
Onkologie|June 14, 2006
Correlation of ErbB2 gene status, mRNA and protein expressionMaurizio D'Incalci
European Journal of Cancer (Oxford, England : 1990)|May 3, 2005
Are we close to the clinical development of novel drugs targeting telomeres and telomerase?Maurizio D'Incalci, Gabriella Zupi
Expert Opinion on Investigational Drugs|October 31, 2003
Preclinical and clinical results with the natural marine product ET-743Maurizio D'Incalci, José Jimeno
Tumori|May 28, 2011
Problems in dealing with very rare adverse effects of new anticancer drugs: the example of trabectedinFederica Grosso, Maurizio D'Incalci
European Journal of Cancer (Oxford, England : 1990)|September 19, 2009
Contemporary pre-clinical development of anticancer agents--what are the optimal preclinical models?Giovanna Damia, Maurizio D'Incalci
Pageof 24